Adaptive Biotechnologies (ADPT) EBIT Margin (2018 - 2026)

Adaptive Biotechnologies has disclosed EBIT Margin across 9 years of filings, most recently posting 27.1% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 27.1%, up 2935.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15.82% (up 5984.0% YoY), and the FY2025 annual result was 20.62%, up 7021.0% from the prior year.
• EBIT Margin came in at 27.1% for Q1 2026 at Adaptive Biotechnologies, down from 17.82% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 10.95% in Q3 2025 to a low of 621.01% in Q2 2023.
• The 5-year median for EBIT Margin is 94.98% (2022), against an average of 118.39%.
• Across the five-year window, EBIT Margin plunged 50076 bps in 2023 and jumped 51146 bps in 2024, its largest moves.
• Adaptive Biotechnologies' EBIT Margin stood at 70.99% in 2022, then plunged by 119 bps to 155.22% in 2023, then soared by 54 bps to 71.3% in 2024, then jumped by 75 bps to 17.82% in 2025, then sank by 52 bps to 27.1% in 2026.
• The last three EBIT Margin figures came in at 27.1% (Q1 2026), 17.82% (Q4 2025), and 10.95% (Q3 2025), per Business Quant data.